DTIL news

Precision BioSciences has dosed the first patient in the Phase 1/2 FUNCTION-DMD trial for DMD, marking a significant clinical development milestone for the company's ARCUS gene-editing platform.

PBGENE-HBV achieved first biopsy evidence of cccDNA elimination, while the company reported Q2 2026 results and a cash balance of $112.4 million.

Precision BioSciences announced the promotion of Alex Kelly to COO and Naresh Tanna to CFO. These changes support the advancement of its gene editing programs PBGENE-HBV and PBGENE-DMD.

Precision BioSciences announced late-breaking clinical data from the ELIMINATE-B study demonstrating that PBGENE-HBV directly eliminated cccDNA with a 10-fold reduction in viral transcripts and achieved pgRNA loss in 100% of treated patients. The data represent a potential breakthrough in hepatitis …

Precision BioSciences adopted a certificate amendment expanding protections for directors and officers from personal liability for breaches of fiduciary duty, subject to Delaware law limits. The amendment enhances corporate governance flexibility and director indemnification provisions.